Author | Gina Columbus | OncLive

Author | Gina Columbus


Entrectinib Approved in Europe for NTRK+ Tumors and ROS1+ NSCLC

August 03, 2020


The European Commission has approved entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non—small cell lung cancer not previously treated with ROS1 inhibitors.

FDA Grants Adjuvant Osimertinib Breakthrough Status in Early-Stage EGFR+ NSCLC

July 30, 2020


The FDA has granted a breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with stage IB, II, and IIIA EGFR-mutated non–small cell lung cancer following complete resection with curative intent.

FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory MCL

July 24, 2020


The FDA has approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Adjuvant Osimertinib Possesses Potential to Revolutionize NSCLC Treatment, But Longer Follow-Up Needed

July 23, 2020


The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.